What is the recommended antiviral treatment and dosage for an otherwise healthy adult male with an initial genital herpes simplex infection?

Treatment of Herpes Simplex in Men

For an initial/first episode of genital herpes in an otherwise healthy adult male, treat with oral acyclovir 400 mg three times daily for 7-10 days, or alternatively valacyclovir 1 g twice daily for 7-10 days. 1

First Episode Treatment

The 1998 CDC guidelines provide the most comprehensive treatment framework, offering multiple equivalent options 1:

Recommended regimens for first clinical episode:

• Acyclovir 400 mg orally 3 times daily for 7-10 days, OR
• Acyclovir 200 mg orally 5 times daily for 7-10 days, OR
• Valacyclovir 1 g orally twice daily for 7-10 days, OR
• Famciclovir 250 mg orally 3 times daily for 7-10 days

Treatment may be extended beyond 10 days if healing is incomplete. The higher-dose acyclovir regimen (400 mg) or valacyclovir offers better compliance due to less frequent dosing compared to the 200 mg five-times-daily regimen 1, 2.

Important Clinical Considerations

• Avoid topical acyclovir - it is substantially less effective than oral therapy and does not improve systemic symptoms 3, 4
• Obtain viral culture or PCR before initiating treatment to confirm diagnosis and determine HSV type (HSV-1 vs HSV-2), which has prognostic importance for recurrence frequency 1, 5
• Treatment provides partial control of symptoms but does not eradicate latent virus or prevent future recurrences 3

Recurrent Episodes

For recurrent genital herpes, treatment should be initiated at the first sign of prodrome or lesions 1:

Episodic treatment options:

• Acyclovir 400 mg orally 3 times daily for 5 days, OR
• Acyclovir 800 mg orally twice daily for 5 days, OR
• Valacyclovir 500 mg orally twice daily for 5 days, OR
• Famciclovir 125 mg orally twice daily for 5 days

Key point: Treatment must be started within 1 day of lesion onset or during prodrome to provide meaningful benefit 1.

Suppressive Therapy

For men with frequent recurrences (≥6 episodes per year), daily suppressive therapy reduces recurrence frequency by ≥75% 1, 3:

Suppressive regimens:

• Acyclovir 400 mg orally twice daily (most established), OR
• Valacyclovir 500-1000 mg orally once daily, OR
• Famciclovir 250 mg orally twice daily

Clinical management of suppression:

• Safety and efficacy documented for acyclovir up to 6 years 1
• After 1 year of continuous therapy, discontinue to reassess recurrence rate 1, 3
• Suppressive therapy reduces but does not eliminate asymptomatic viral shedding 1
• Valacyclovir 500 mg once daily is less effective in patients with very frequent recurrences (≥10 episodes/year) 1

Severe Disease

For severe disease requiring hospitalization (disseminated infection, pneumonitis, hepatitis, meningitis, encephalitis):

• Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution 1

Special Situation: HSV-2 Meningitis

For first episode HSV-2 meningitis: acyclovir 10 mg/kg IV every 8 hours until fever/headache resolve, then valacyclovir 1 g three times daily to complete 14 days 6. This is distinct from HSV encephalitis, which requires 14-21 days of IV acyclovir.

Essential Patient Counseling

Comprehensive counseling is critical and should include 1:

• Natural history: Emphasize potential for recurrent episodes and asymptomatic viral shedding
• Transmission risk: Advise abstaining from sexual activity when lesions or prodromal symptoms present
• Condom use: Encourage consistent use with new or uninfected partners
• Asymptomatic shedding: Explain that transmission can occur even without visible lesions, particularly in the first 12 months after infection
• Partner notification: Inform current and future sexual partners about the infection

Common Pitfalls to Avoid

1. Don't use topical acyclovir - substantially inferior to oral therapy
2. Don't delay treatment - efficacy depends on early initiation, ideally within 24 hours of symptom onset
3. Don't assume treatment prevents latency - antivirals control symptoms but don't eradicate the virus
4. Don't continue suppressive therapy indefinitely without reassessment - evaluate need after 1 year
5. Don't confuse HSV meningitis with encephalitis - the latter requires prolonged IV therapy and has much higher morbidity/mortality

The evidence strongly supports oral antiviral therapy as first-line treatment, with acyclovir and valacyclovir having the most extensive safety and efficacy data. Valacyclovir offers improved bioavailability and more convenient dosing, which may enhance compliance 2.